CClinicalTrials.gg
CompletedNCT02590549Updated Oct 29, 2015

MyoRing Implantation With Corneal Collagen Crosslinking for Keratoconus

An interventional study of Corneal Collagen Crosslinking and Ufalink in Keratoconus, sponsored by Ufa Eye Research Institute. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Ufa Eye Research Institute · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A complete intrastromal ring, MyoRing (Dioptex, GmbH, Linz, Austria), suggested by Albert Daxer in 2007, is a relatively new technique that has been demonstrated to treat keratoconus safely and effectively.Corneal collagen crosslinking (CXL), introduced by Wollensak et al. in 2003, has become a standard treatment for progressive keratoconus to slow or possibly stop progression of disease.

The formation of the stromal pocket during MyoRing implantation offers the opportunity for simultaneous introduction of riboflavin 0.1% into the pocket followed by UVA irradiation to provide combined treatment in patients with progressive keratoconus.

02

Conditions studied

  • Keratoconus

Browse trials for

Keywords

  • Keratoconus
  • riboflavin
  • corneal collagen crosslinking
  • intrasromal ring
03

In context

Keratoconus

307 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's enrollment of 16 is below the median of 40 across 203 interventional studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Ufa Eye Research Institute is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • >18 years old
  • a diagnosis of keratoconus, intolerance for contact lenses or glasses
  • a documented progression of disease. This progression was defined by the following changes over 1 year: an increase of the steepest K by 1.0 diopter (D) or more in manifest cylinder, or an increase of 0.5 D or more in manifest spherical equivalent (SE) refraction by repeated keratotopography ODP-scan ARK-1000 (Nidek, Japan)

Exclusion criteria

Exclusion Criteria:

  • minimal pachymetry of less than 380 μm,
  • a history of previous ocular pathology or ocular surgery;
  • pregnancy or breastfeeding;
  • corneal scarring.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    MyoRing Implantation combined with corneal cross linking

    Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)

    Procedure: Corneal Collagen Crosslinking · Device: Ufalink

Interventions

  • ProcedureCorneal Collagen Crosslinking

    Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel. Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes. After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,

  • DeviceUfalink

    UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation

06

What researchers measure

Primary outcomes

  1. K max

    Using topography measurements, decrease of maximum keratometry value over the preoperative maximum keratometry value

    Time frame: 2 years

Secondary outcomes

  1. Visual acuity as assessed by Decimal system

    Decimal visual acuity assessed on a study later was converted to the logarithm of minimal angle of resolution (logMAR).

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Jadidi K, Mosavi SA, Nejat F, Naderi M, Janani L, Serahati S. Intrastromal corneal ring segment implantation (keraring 355 degrees ) in patients with central keratoconus: 6-month follow-up. J Ophthalmol. 2015;2015:916385. doi: 10.1155/2015/916385. Epub 2015 Jan 5. PubMed 25685395 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02590549
Lead sponsor
Ufa Eye Research Institute
Responsible party
Sponsor
First posted
Oct 29, 2015
Start date
Jan 2011
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Oct 29, 2015

Study contacts

Mukharram Bikbov, Professor
study chair · Ufa Eye Research Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion